make adjust coupl model ahead earn
chang est lower ep vs con
ep vs con recalibr opm expect
slightli lower revenue growth model reflect
dilut impact recent sale cryosurg unit nh lower rev
reduc test forecast
buy pt make chang estim ahead print
next week trim ep forecast mainli reflect less
aggress oper margin expans assumpt feel comfort
revenu case volum q/q vs q/q average past
four yr forecast taken conserv stanc around opm
assumpt vs prior take ep slightli
consensu trim ep forecast
still consensu slightli lower top-lin growth opm
expect vs prior maintain buy rate pt
stock impli ev rev compar high-growth
hold pt updat model account recent
divestitur cryosurg system busi complet august
revenu forecast move lower respect
ep goe exclud gain book
sale ep move lost revenu op
contribut cryo unit high level think divestitur logic
strateg move non-cor asset financi impact harder ration
cryo unit contribut ebit sold ebit
nh buy pt trim rev respect mainli
lower test volum expect cancer test
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
summari chang
ep reflect non-gaap ep exclud sbc expens amort discret item
pleas see import disclosur inform page report
pleas see import disclosur inform page report
inc histor project statement incomedollar million except per share amountshistor net product expens loss share share analysisgross research sale oper incom net growth analysisnet jefferi co equiti research
pleas see import disclosur inform page report
orasur technologieshistor project statement incomedollar million except per share amount fiscal year end decemb histor net product administr expens share share ep analysiscorpor gross gross administr analysisnet administr orasur technolog jefferi llc exhibit nh incom statement
pleas see import disclosur inform page report
histor cancer good expens expens incom equiti method share share ep ep non- excl analysi gross margin research sg oper net analysisnet research sg nanthealth jefferi llc align technolog inc
revenu invisalign case
nopat compound-annual-growth-rate next decad
price target impli ev ebitda
faster adopt mandibular advanc
improv better mix ou growth
invisalign go north america
growth year target annual growth
stepped-up promo activ advers mix shift
return
expect achiev sustain above-averag
organ revenu growth improv profit owe
highli differenti product offer innov
new product innov pipelin greenfield intenational
new competit entrant recent emerg
algn moat wider perceiv view
invisalign penetr new greenfield intenational market
uptak mandibular advanc us
addit traction i-tero larg dso
pleas see import disclosur inform page report
reflect non-gaap ep exclud sbc expens amort discret item
rev
revenu
technolog solut sale
proceed plan
new reimburs contract
coverag
valuat pt impli ev/rev par
hcit comp
revenu
order patient w/ cvg fda approv
improv traction roll-out larg self-
revenu flattish trend hcit
ramp
weaker expect test volum ramp new
payor win fda approv
exist implement complet new sale
higher commerci invest need drive
platform success nanthealth technolog
solut histor sold stand-alone
basi continu extent though
manag expect major growth go
forward driven bundl
test therefor success nh much
depend upon interdepend diagnost
technolog platform help doc interpret
act upon test find
increment reimburs coverag new
increment public scientif evid
support clinic valid util
pleas see import disclosur inform page report
dnag improv hiv self-test
contribut potenti
price target impli ev revenue
faster traction microbiom sale servic
offer pharma/biotech
price target impli ev revenu
price target impli ev revenu
like osur exposur consum genom
space novel oral fluid sampl collect
devic de-facto gold standard
nearli cash debt b/ option
could upsid factor strong funnel
pleas see import disclosur inform page report
